IP Library › Granted Patent US 12,296,125
Granted Patent B2
US 12,296,125 · App. 17/387,855 · Granted May 13, 2025

3-dimensional large capacity cell encapsulation device assembly

Inventors: Vincent So (San Diego, CA); Laura Martinson (San Diego, CA); Chad Green (San Diego, CA); Michael Scott (San Diego, CA); Mario Zamarripa (San Diego, CA)
Assignee: ViaCyte, Inc.
A61M31/002A61F2/022A61M2202/09A61M2205/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,296,125
App. No.
17/387,855
Granted
May 13, 2025
Kind
B2
Abstract

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

Claims (13)

1. A cell encapsulation assembly, said assembly comprising a length, a width, first and second opposing long sides extending lengthwise of the assembly, and first and second opposing short sides extending widthwise of the assembly, wherein the assembly has a longest axis extending lengthwise of the assembly, the assembly further comprising at least two planar cell chambers and a cell-free region along the longest axis separating adjacent planar cell chambers, wherein each chamber is fluidly separated from another chamber, and each chamber comprises a semi-permeable membrane comprising an inner surface configured to be in contact with cells that are placed in the respective chamber, wherein each chamber has at least one loading port extending from outside of the chamber to inside of the chamber, wherein each chamber is configured to be sealed to contain the cells that are placed in the respective chamber, and at least a portion of an outer surface of the cell encapsulating assembly is configured to be placed in direct contact with host tissue upon implantation of the cell encapsulating assembly into a mammalian host, wherein the assembly comprises at least one suture tab at the first short side of the assembly for securing the assembly at an implantation site inside the host, wherein each loading port extends from outside of the respective chamber to inside of the respective chamber at the second short side of the assembly, and wherein the cell-free region is bent.

2. The assembly of claim 1 , further comprising cells contained within the cell chambers.

3. The assembly of claim 2 , wherein the cells are human definitive endoderm-lineage cells, human pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells, human endocrine precursor cells, or human immature beta cells.

4. The assembly of claim 1 , wherein each chamber has at least two loading ports extending from outside of the chamber to inside of the chamber.

5. The assembly of claim 1 , wherein the assembly comprises a first layer of semipermeable material and a second layer of semipermeable material forming the cell chambers therebetween, wherein the first and second layers are secured to each other at locations between the cell chambers to form the cell free region.

6. The assembly of claim 5 , wherein the cell-free region comprises a welded region bonding the first and second layers to each other.

7. The assembly of claim 6 , wherein the welded region extends between and intersects the first and second short sides of the assembly.

8. The assembly of claim 1 , wherein the tab extends lengthwise of the assembly from the first short side.

9. The assembly of claim 8 , wherein the tab has a rounded peripheral edge.

10. The assembly of claim 1 , wherein the tab comprises two suture tabs at the first short side of the assembly, wherein the two tabs are spaced apart from each other widthwise of the assembly.

11. The assembly of claim 10 , each tab extends from an intersection of an end of the first short side and an adjacent end of one of the long sides.

12. The assembly of claim 10 , wherein the tabs extend lengthwise of the assembly from the first short side.

13. The assembly of claim 1 , wherein an angle between the cell chambers is less than 175 degrees.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2021
From: SO, VINCENT; GREEN, CHAD; MARTINSON, LAURA; SCOTT, MICHAEL; ZAMARRIPA, MARIO
To: VIACYTE, INC.
Reel/Frame 057313/0913 →
Continuity (4)
Continuation 15349787 · Nov 11, 2016
Continuation 14201630 · Mar 7, 2014
Provisional Application 61774443 · Mar 7, 2013
Related Publication 20220016406A1 · Jan 20, 2022
References Cited (135)
US 2500388A · Simons · 1950 [cited by applicant]
US 2519983A · Simons · 1950 [cited by applicant]
US 2594272A · Kauck et al. · 1952 [cited by applicant]
US 2616927A · Kauck et al. · 1952 [cited by applicant]
US 3616930A · Muir · 1971 [cited by applicant]
US 3929971A · Roy · 1975 [cited by applicant]
US 4298002A · Ronel et al. · 1981 [cited by applicant]
US 4723953A · Rosenbaum et al. · 1988 [cited by applicant]
US 4788339A · Moore et al. · 1988 [cited by applicant]
US 4968733A · Muller et al. · 1990 [cited by applicant]
US 4976859A · Wechs · 1990 [cited by applicant]
US 5011494A · Recum et al. · 1991 [cited by applicant]
US 5026365A · Rossini et al. · 1991 [cited by applicant]
US 5100392A · Orth et al. · 1992 [cited by applicant]
US 5158881A · Aebischer et al. · 1992 [cited by applicant]
US 5219361A · Recum et al. · 1993 [cited by applicant]
US 5284761A · Aebischer et al. · 1994 [cited by applicant]
US 5314471A · Brauker et al. · 1994 [cited by applicant]
US 5324518A · Orth et al. · 1994 [cited by applicant]
US 5344454A · Clarke et al. · 1994 [cited by applicant]
US 5421923A · Clarke et al. · 1995 [cited by applicant]
US 5453278A · Chan et al. · 1995 [cited by applicant]
US 5545223A · Neuenfeldt et al. · 1996 [cited by applicant]
US 5549675A · Neuenfeldt et al. · 1996 [cited by applicant]
US 5554148A · Aebischer et al. · 1996 [cited by applicant]
US 5569462A · Martinson et al. · 1996 [cited by applicant]
US 5593440A · Brauker et al. · 1997 [cited by applicant]
US 5605693A · Seare · 1997 [cited by applicant]
US 5624674A · Seare · 1997 [cited by applicant]
US 5653756A · Clarke et al. · 1997 [cited by applicant]
US 5713888A · Neuenfeldt et al. · 1998 [cited by applicant]
US 5733336A · Neuenfeldt et al. · 1998 [cited by applicant]
US 5738673A · Mills et al. · 1998 [cited by applicant]
US 5741330A · Brauker et al. · 1998 [cited by applicant]
US 5782912A · Brauker et al. · 1998 [cited by applicant]
US 5800529A · Brauker et al. · 1998 [cited by applicant]
US 5807406A · Brauker et al. · 1998 [cited by applicant]
US 5882354A · Brauker et al. · 1999 [cited by applicant]
US 5902745A · Butler et al. · 1999 [cited by applicant]
US 5913998A · Butler et al. · 1999 [cited by applicant]
US 5964261A · Neuenfeldt et al. · 1999 [cited by applicant]
US 5964804A · Brauker et al. · 1999 [cited by applicant]
US 6060640A · Pauley et al. · 2000 [cited by applicant]
US 6156305A · Brauker et al. · 2000 [cited by applicant]
US 6365385B1 · Opara · 2002 [cited by applicant]
US 6520997B1 · Pekkarinen et al. · 2003 [cited by applicant]
US 6617151B1 · Newman et al. · 2003 [cited by applicant]
US 6773458B1 · Brauker et al. · 2004 [cited by applicant]
US 7192450B2 · Brauker et al. · 2007 [cited by applicant]
US 7510876B2 · D'Amour et al. · 2009 [cited by applicant]
US 7534608B2 · Martinson et al. · 2009 [cited by applicant]
US 7541185B2 · D'Amour et al. · 2009 [cited by applicant]
US 7625753B2 · Kelly et al. · 2009 [cited by applicant]
US 7695963B2 · Agulnick et al. · 2010 [cited by applicant]
US 7695965B2 · Martinson et al. · 2010 [cited by applicant]
US 7704738B2 · D'Amour et al. · 2010 [cited by applicant]
US 7958585B2 · Zhang et al. · 2011 [cited by applicant]
US 7993916B2 · Agulnick et al. · 2011 [cited by applicant]
US 7993920B2 · Martinson et al. · 2011 [cited by applicant]
US 8008075B2 · Green et al. · 2011 [cited by applicant]
US 8129182B2 · D'Amour et al. · 2012 [cited by applicant]
US 8178878B2 · Chien et al. · 2012 [cited by applicant]
US 8211699B2 · Robins et al. · 2012 [cited by applicant]
US 8216836B2 · D'Amour et al. · 2012 [cited by applicant]
US 8278106B2 · Martinson et al. · 2012 [cited by applicant]
US 8334138B2 · Robins et al. · 2012 [cited by applicant]
US 8338170B2 · Kelly et al. · 2012 [cited by applicant]
US 8425928B2 · Martinson et al. · 2013 [cited by applicant]
US 8623645B2 · D'Amour et al. · 2014 [cited by applicant]
US 8758799B2 · Stopek et al. · 2014 [cited by applicant]
US 9526880B2 · So et al. · 2016 [cited by applicant]
US 11077289B2 · So · 2021 [cited by examiner]
US 20040208909A1 · Brubaker · 2004 [cited by examiner]
US 20050260623A1 · Trosko et al. · 2005 [cited by applicant]
US 20080039792A1 · Meng · 2008 [cited by examiner]
US 20090105811A1 · Dinh et al. · 2009 [cited by applicant]
US 20100124564A1 · Martinson et al. · 2010 [cited by applicant]
US 20110236457A1 · Kauper et al. · 2011 [cited by applicant]
US 20110287071A1 · Mitrani et al. · 2011 [cited by applicant]
US 20120245705A1 · Hasilo et al. · 2012 [cited by applicant]
US 20150030657A1 · Ludlow et al. · 2015 [cited by applicant]
CA 2190628A1 · 1996 [cited by applicant]
CA 2190628C · 2000 [cited by applicant]
CA 2443070A1 · 2004 [cited by applicant]
CA 2437250A1 · 2005 [cited by applicant]
WO 9102498A1 · 1991 [cited by applicant]
WO 9110425A1 · 1991 [cited by applicant]
WO 9219195A1 · 1992 [cited by applicant]
WO 9300128A1 · 1993 [cited by applicant]
WO 9300439A1 · 1993 [cited by applicant]
WO 1993000128A1 · 1993 [cited by applicant]
WO 9321902A1 · 1993 [cited by applicant]
WO 9505452A2 · 1995 [cited by applicant]
WO 9518584A1 · 1995 [cited by applicant]
WO 9528166A2 · 1995 [cited by applicant]
WO 9610966A1 · 1996 [cited by applicant]
WO 9632076A1 · 1996 [cited by applicant]
WO 9639100A1 · 1996 [cited by applicant]
WO 1996039100A1 · 1996 [cited by applicant]
WO 9953021A1 · 1999 [cited by applicant]
WO 03059072A1 · 2003 [cited by applicant]
WO WO2005063204A2 · 2005 [cited by examiner]
WO 2008112190A1 · 2008 [cited by applicant]
WO 2008079997A3 · 2008 [cited by applicant]
WO 2010057039A2 · 2010 [cited by applicant]
WO 2010121024A2 · 2010 [cited by applicant]
WO 2012115619A1 · 2012 [cited by applicant]
Ronel et al. “Macroporous hydrogel membranes for a hybrid artificial pancreas. I. Synthesis and chamber fabrication.” Journal of Biomedical Materials Research, vol. 17,855-864 (1983). (Year: 1983). [cited by examiner]
“Communication—European Search Report” from the European Patent Office for European Application No. EP18167634.7-1113, dated Dec. 9, 2020, 6 pages. [cited by applicant]
Alink et al., “The Effect of Cooling Rate and of Dimethyl Sulfoxide Concentration on Low Temperature Preservation of Neonatal Rat Heart Cells”, Cryobio/ogy, 1976, vol. 13, p. 295-304. [cited by applicant]
Bank et al., “Cryogenic Preservation of Rat Polymorphonuclear Leukocytes”, Blood Cells, 1980, vol. 6, p. 65-81. [cited by applicant]
Baust et al., “Modulation of the cryopreservation cap: elevated survival with reduced dimethyl sulfoxide concentration”, Cryobiology, 2002, vol. 45, p. 97-108. [cited by applicant]
Brauker et al., “Neovascularization of synthetic membranes directed by membrane microarchitecture”, Journal of Biomedical Materials Research, 29:1517-1524; 1995. [cited by applicant]
Brauker et al., “Local inflammatory response around diffusion chambers containing xenografts.Nonspecific destruction of tissues and decreased local vascularization”, Transplantation 61(12):1671-1677; 1996. [cited by applicant]
Carlsson et al., “Measurements of Oxygen Tension in Native and Transplanted Rat Pancreatic Islets”, Diabetes 47(7):1027-1032; 1998. [cited by applicant]
Chung et al., “Human Embryonic Stem Cell Lines Generated without Embryo Destruction”, Cell Stem Cell, 2(2), 113-117; 2008. [cited by applicant]
Design U.S. Appl. No. 29/408,366, filed Dec. 12, 2011. [cited by applicant]
Design U.S. Appl. No. 29/408,368, filed Dec. 12, 2011. [cited by applicant]
Design U.S. Appl. No. 29/408,370, filed Dec. 12, 2011. [cited by applicant]
Design U.S. Appl. No. 29/423,365, filed May 31, 2012. [cited by applicant]
Dionne et al., “Effect of Oxygen on Isolated Pancreatic Tissue”, Trans. Am. Soc. Artf. Intern. Organs, 35: 739-741; 1989. [cited by applicant]
International Preliminary Report on Patentability dated Sep. 17, 2015, issued in connection with corresponding International Application No. PCT/US14/022109 (6 pages total). [cited by applicant]
International Search Report and Written Opinion dated Jun. 26, 2014 for International Application No. PCT/US2014/022109, 9 pages. [cited by applicant]
Klimanska Ya et al., “Human embryonic stem cell lines derived from single blastomeres”, Nature, 444:481-485; 2006. [cited by applicant]
Korsgren et al., “Current Status of Clinical Islet Transplantation”, Transplantation 79(10):1289-1293; 2005. [cited by applicant]
Kumagai-Braesch et al., The TheraCyte TM Device Protects against Islet AI log raft Rejection in Immunized Hosts, Cell Transplantation, 22:1137-1146; 2013. [cited by applicant]
Loudovaris et al., “CD4+ T cell mediated destruction of xenografts within cell-impermeable membranes in the absence of CD8+ T cells and B cells”, Transplantation 61:1678-1684; 1996. [cited by applicant]
Loudovaris et al., “Destruction of Xenografts But Not Allografts Within Cell Impermeable Membranes”, Transplantation Proceedings 24:2291-2292; 1992. [cited by applicant]
McKenzie et al., “Protection of Xenografts by a Combination of Immunoisolation and a Single Dose of Anti-CD4 Antibody”, Cell Transplantation 10: 183-193; 2001. [cited by applicant]
Rice et al., “Quantitative biomarkers of stem cell differentiation based on intrinsic two-photon excited fluorescence”, Journal of Biomedical Optics Nov.-Dec. 2007; 12(6), 3 pages. [cited by applicant]
Tibell et al., “Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year After Transplantation in Nonimmunosuppressed Humans”, Cell Transplantation. 10:591-599; 2001. [cited by applicant]
U.S. Appl. No. 13/672,688, filed Nov. 8, 2012. [cited by applicant]
U.S. Appl. No. 13/761,078, filed Feb. 6, 2013. [cited by applicant]
U.S. Appl. No. 14/106,330, filed Dec. 13, 2013. [cited by applicant]
Vertex Pharmaceuticals Incorporated, “Vertex to acquire ViaCyte, with the goal of accelerating its potentially curative VX-880 programs in Type 1 Diabetes,” Press Release (Jul. 11, 2022) (2 pages). [cited by applicant]